Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dipraglurant
- Development stage
- Phase 3
- Lead developer
- Addex Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dipraglurant is a small molecule negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). It is being developed primarily by Addex Therapeutics for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease. The drug works by reducing abnormal glutamate signaling, which contributes to dyskinesia and other motor symptoms in Parkinson’s disease. In addition to LID, dipraglurant has been investigated in clinical trials for dystonia, blepharospasm, major depressive disorder, stroke recovery, traumatic brain injury recovery, and other neurological conditions. It is administered orally and has shown rapid absorption and central nervous system penetration in preclinical studies[1][2][3][4][6].
- Other names
- Dipraglurant-ERDipraglurant-IRDipraglurant-MR
02
Targets
GRM5 (Metabotropic glutamate receptor 5)
Beyond the preview
Go deeper on dipraglurant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dipraglurant.